Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 488-492

  May, Taymaa ^a   Shoni, Melina ^a   Crum, Christopher P ^a   Xian, Wa ^a   Vathipadiekal, Vinod ^b   Birrer, Michael ^b   Rosen, Barry ^c   Tone, Alicia ^d   Murphy, K Joan ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Fallopian tube carcinoma; Gene expression analysis; High grade serous carcinoma; Low grade serous carcinoma; Ovarian carcinoma; Taxane resistance

Indexed keywords

IMATINIB; PACLITAXEL; TAXANE DERIVATIVE;

ADD ON THERAPY; ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESISTANCE; CARCINOGENESIS; DISEASE ACTIVITY; GENE EXPRESSION; GENE REPRESSION; HIGH GRADE SEROUS CARCINOMA; HUMAN; LOW GRADE SEROUS CARCINOMA; OVARY CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; SEROUS MULLERIAN CARCINOMA; STANDARD; TREATMENT RESPONSE;

CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIXED TUMOR, MULLERIAN; NEOPLASM GRADING; OVARIAN NEOPLASMS; TRANSCRIPTOME;

EID: 84873713376     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.009     Document Type: Article

References (60)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. K.R. Cho, and I.M. Shih Ovarian cancer Annu Rev Pathol Mech Dis 4 2009 287 313
3. C.N. Landen Jr., M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol 26 2008 995 1005
4. IeM Shih, and R.J. Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 2004 1511 1518
5. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
6. P. Bichel, and A. Jakobsen A new histologic grading index in ovarian carcinoma Int J Gynecol Pathol 8 1989 147 155
7. Y. Shimizu, S. Kamoi, S. Amada, K. Hasumi, F. Akiyama, and S.G. Silverberg Toward the development of a universal grading system for ovarian epithelial carcinoma. Prognostic significance of histopathologic features - Problems involved in the architectural grading system Gynecol Oncol 70 1998 2 12
8. S.G. Silverberg Histopathologic grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol 19 2000 7 15
9. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, and D.M. Gershenson Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
10. A. Malpica, M.T. Deavers, C. Tornos, R.J. Kurman, R. Soslow, and J.D. Seidman Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma Am J Surg Pathol 31 8 Aug 2007 1168 1174
11. J.D. Seidman, I. Horkayne-Szakaly, J.A. Cosin, H.S. Ryu, M. Haiba, and C.R. Boice Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum Gynecol Oncol 103 2 2006 703 708
12. G. Singer, R.J. Kurman, H.W. Chang, S. Cho, and I.-M. Shih Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 4 2002 1223 1228
13. T. May, C. Virtanen, M. Sharma, A. Milea, H. Begley, and B. Rosen Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary Gynecol Oncol 117 1 Apr 2010 9 17
14. J.M. Piek, P.J. van Diest, R.P. Zweemer, P. Kenemans, and R.H. Verheijen Tubal ligation and risk of ovarian cancer Lancet 358 2001 844
15. C.P. Crum, R. Drapkin, A. Miron, T.A. Ince, M. Muto, and D.W. Kindelberger The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 1 2007 3 9
16. A.A. Tone, H. Begley, M. Sharma, J. Murphy, B. Rosen, and T.J. Brown Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma Clin Cancer Res 14 13 2008 4067 4078
17. P.A. Shaw, M. Rouzbahman, E.S. Pizer, M. Pintilie, and H. Begley Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers Mod Pathol 22 9 2009 1133 1138
18. C.J. O'Neill, M.T. Deavers, A. Malpica, H. Foster, and W.G. McCluggage An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms Am J Surg Pathol 29 2005 1034 1041
19. H.F. Wong, J.J. Low, Y. Chua, I. Busmanis, E.H. Tay, and T.H. Ho Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004 Int J Gynecol Cancer 17 2007 342 349
20. G. Singer, R. Oldt, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
21. G. Singer, R. Stohr, L. Cope, R. Dehari, A. Hartmann, and D.F. Cao Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 2005 218 224
22. C.B. Gilks Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data Int J Gynecol Pathol 23 2004 200 205
23. C.Y. Hsu, R. Bristow, M.S. Cha, B.G. Wang, C.L. Ho, and R.J. Kurman Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas Clin Cancer Res 10 2004 6432 6436
24. G. Singer, M. Shih le, A. Truskinovsky, H. Umudum, and R.J. Kurman Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) Int J Gynecol Pathol 22 2003 37 41
25. T. Bonome, J.Y. Lee, D.C. Park, M. Radonovich, C. Pise-Masison, and J. Brady Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 2005 10602 10612
26. A.A. Jazaeri, K. Lu, R. Schmandt, C.P. Harris, P.H. Rao, and C. Sotiriou Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma Mol Carcinog 36 2003 53 59
27. I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitrov, L.M. Sapinoso, and M. Orlowska-Volk Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential Oncogene 24 2005 1053 1065
28. A.P. Heintz, F. Odicino, P. Maisonneuve, U. Beller, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. 25th annual report on the results of treatment of gynecological cancer Int J Gynecol Obstet 83 2003 135 166
29. D.M. Gershenson, C. Sun, D. Bodurka, R.L. Coleman, K.H. Lu, and A.K. Sood Recurrent low grade serous carcinoma of the ovary is relatively chemoresistant Gynecol Oncol 108 1 2008 S5
30. J.A. Lachance, J. Shutter, K.A. Atkins, M.H. Stoler, L.W. Rice, and A.A. Jazaeri Utilization of a uniform grading system for interpreting serous ovarian cancer Am J Obstet Gynecol 199 2 Aug 2008 189 [e1-6]
31. K.M. Schmeler, C.C. Sun, D.C. Bodurka, M.T. Deavers, A. Malpica, and R.L. Coleman Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 108 2008 510 514
32. K.M. Schmeler, and D.M. Gershenson Low-grade serous ovarian cancer: a unique disease Curr Oncol Rep 10 6 2008 519 523
33. D.M. Gershenson, C.C. Sun, K.H. Lu, R.L. Coleman, A.K. Sood, and A. Malpica Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary Obstet Gynecol 108 2 2006 361 368
34. R.E. Bristow, D.R. Gossett, D.R. Shook, M.L. Zahurak, R.S. Tomacruz, and D.K. Armstrong Micropapillary serous ovarian carcinoma: surgical management and clinical outcome Gynecol Oncol 86 2002 163 170
35. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 1996 1 6
36. G.C. Stuart, H. Kitchener, M. Bacon, A. duBois, M. Friedlander, and J. Ledermann 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference Int J Gynecol Cancer 21 4 2011 750 755
37. T. Thigpen, G. Stuart, A. du Bois, M. Friedlander, K. Fujiwara, and J.P. Guastalla Gynecologic Cancer Intergroup; GOG; NCIC-CTG; AGO-OVAR; ANZGOG; JGOG; GINECO; SGCTG, MRC/NCRI, NSGO, RTOG, GEICO; EORTC. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens Ann Oncol 16 Suppl. 8 2005 viii13 viii19
38. A.P.M. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. 26th annual report on the results of treatment in gynecological cancer Int J Gynecol Obstet 95 S1 2006 [S161-92]
39. C.J. O'Neill, M.T. Deaver, A. Malpica, H. Foster, and W.C. McCluggage An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinoma: significantly higher expression of p53, MIB1, BCL2, HER-2/Neu, and C-KIT in high-grade neoplasms Am J Surg Pathol 29 8 2005 1034 1041
40. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
41. M.S. Anglesio, J.M. Arnold, J. George, A.V. Tinker, R. Tothill, and N. Waddell Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors Mol Cancer Res 6 11 Nov 2008 1678 1690
42. N.J. Bowen, L.D. Walker, L.V. Matyunina, S. Logani, K.A. Totten, and B.B. Benigno Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells BMC Med Genomics 2 Dec 29 2009 71
43. S.C. Mok, T. Bonome, V. Vathipadiekal, A. Bell, M.E. Johnson, and K.K. Wong A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2 Cancer Cell 16 6 Dec 8 2009 521 532
44. C.S. Tung, S.C. Mok, Y.T. Tsang, Z. Zu, H. Song, and J. Liu PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas Mod Pathol 22 9 Sep 2009 1243 1250
45. E. Iorio, A. Ricci, M. Bagnoli, M.E. Pisanu, G. Castellano, and M. Di Vito Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells Cancer Res 70 5 Mar 1 2010 2126 2135
46. R.A. Irizarry, B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, and U. Scherf Exploration, normalization, and summaries of high density oligonucleotide array probe level data Biostatistics 4 2 Apr 2003 249 264
47. W.E. Johnson, C. Li, and A. Rabinovic Adjusting batch effects in microarray expression data using empirical Bayes methods Biostatistics 8 1 Jan 2007 118 127
48. A.A. Tone, S. Salvador, S.J. Finlayson, A.V. Tinker, J.S. Kwon, and C.H. Lee The role of the fallopian tube in ovarian cancer Clin Adv Hematol Oncol 10 5 May 2012 296 306
49. B.D. Rowland, and D.S. Peeper KLF4, p21 and context-dependent opposing forces in cancer Nat Rev Cancer 6 1 Jan 2006 11 23
50. D.C. Park, S.G. Yeo, M.R. Wilson, J.J. Yerbury, J. Kwong, and W.R. Welch Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer Neoplasia 10 9 Sep 2008 964 972
51. S.M. Garvey, D.S. Sinden, P.D. Schoppee Bortz, and B.R. Wamhoff Cyclosporine up-regulates Krüppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo J Pharmacol Exp Ther 333 1 Apr 2010 34 42
52. S.M. Apte, D. Fan, J.J. Killion, and I.J. Fidler Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma Clin Cancer Res 10 3 2004 897 908
53. C. Mundhenke, M.T. Weigel, K.H. Sturner, F. Roesel, I. Meinhold-Heerlein, and D.O. Bauerschlag Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects J Cancer Res Clin Oncol 134 12 2008 1397 1405
54. T.J. Shaw, and B.C. Vanderhyden AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate Gynecol Oncol 105 1 2007 122 131
55. I.R. Noguera, C.C. Sun, R.R. Broaddus, D. Branham, C.F. Levenback, and P.T. Ramirez Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube Gynecol Oncol 125 3 Jun 2012 640 645
56. M.J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, C. Mangioni, and E. Simonsen Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gynecol Cancer 13 2003 144 148
57. M. Selvakumaran, D.A. Pisarcik, R. Bao, A.T. Yeung, and T.C. Hamilton Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res 63 2003 1311 1316
58. E. Reed, J.J. Yu, A. Davies, J. Gannon, and S.L. Armentrout Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer Clin Cancer Res 9 2003 5299 5305
59. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat Rev Cancer 3 2003 502 516
60. A.A. Ahmed, X. Wang, Z. Lu, J. Goldsmith, X.F. Le, and G. Grandjean Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel Cancer Res 71 2011 5806 5817